Theagene Jean-Manasse 4

What Happened

• Theagene Jean‑Manasse, a director of MAIA Biotechnology, Inc. (MAIA), received a grant of 27,258 derivative securities (stock options) on 2026-03-31. The transaction is reported as an award (grant) with $0 cash paid in the filing. This was not a purchase or sale of common shares but an option grant.

Key Details

• Transaction date and terms: Grant dated 2026-03-31 — 27,258 options reported at $0.00 (no cash paid reported).
• Vesting/exercisability: Per the filing footnote, the options vest 100% on the grant date and are exercisable beginning that date.
• Shares owned after transaction: Not specified in the provided summary of the Form 4; see the full Form 4 for aggregate holdings and exercise price details.
• Filing timing: Form filed 2026-04-02 (two days after the grant); the filing does not indicate a late report.

Context

• These are option awards (a derivative), meaning the holder has the right to buy common shares under the plan terms; this grant shows immediate vesting and exercisability, so the director could exercise the options per the plan and pay any applicable exercise price. The Form 4 shows the grant amount but does not by itself indicate whether any shares were immediately exercised or sold.